Clinical Study Of Jianpixiaodu Decoction In The Treatment Of CAG-PC And Its Effect On The Expression Of IL-6,IL-11 And TNF-α In Gastric Mucosa

Object:To observe the clinical effect of Jianpixiaodu Decoction on CAG-PC(premalignant conditions based on chronic atrophic gastritis)and its effect on gastric mucosal inflammation-related factors about IL-6,IL-11,TNF-α;To explore the mechanism of this prescription on CAG-PC in order to provide relevant evidence for clinical treatment.Methods:According to the case selection criteria,all the CAG-PC patients collected were given Jianpixiaodu Decoction for 24 weeks(other related drugs for treating CAG-PC were stopped during the treatment period).Observe and compare the clinical effect-as well as TCM syndrome score,main symptom score,gastroscopy,pathology,and expressions of gastric mucosa inflammatory factor about IL-6,IL-11,TNF-α-before treatment with after Jianpixiaodu Decoction treatment on CAG-PC patients.Results:Treatment of CAG-PC with Jianpixiaodu Decoction,the total clinical efficacy:6.67%cure rate,43.33%effective rate,46.67%effective rate,3.33%ineffective rate,96.7%total clinical rate.After treatment,patients’ TCM syndrome scores were significantly lower than before(P<0.01);major symptom scores,gastroscopic and histopathological scores were all improved(P<0.05);Immunohistochemical staining and gray value measurement showed that the positive expression rates of IL-6 and TNF-αdecreased(P<0.05),and there was no statistically significant change in IL-11(P>0.05).Conclusion:Jianpixiaodu Decoction can improve the clinical symptoms,gas-troscopy and histopathological expression on CAG-PC patients.The mechanis m may be related to inhibiting the expression of inflammation-related fac tors such as IL-6 and TNF-α.